Dr. Lal Path Labs Ltd. (LALPATHLAB)

Price2,339.60 -51.35 (-2.15%)52 Week High2,750.00
ISININE600L0102452 Week Low1,762.05
IndustryMedical/Nursing ServicesVolume177.9 T
SectorHealth ServicesP/E Ratio TTM73.86
Market Cap199.4 B1 Year Beta0.54
Technical Rating of

Dr. Lal Path Labs Ltd. (LALPATHLAB) logo

Dr. Lal Path Labs Ltd. (LALPATHLAB) is an Indian diagnostic laboratory chain. It was founded in 1983 and is headquartered in Delhi, India. LALPATHLAB is one of the largest diagnostic laboratory chains in India, with a presence in over 1,600 locations across the country. The company’s services include a wide range of diagnostic tests, including blood tests, imaging tests, and molecular tests.

LALPATHLAB is a well-managed and profitable organization. It has been consistently profitable and has been paying dividends to its shareholders since its inception. The company has a strong track record of innovation, and has introduced a number of new services in recent years.

LALPATHLAB is a good investment option for those who are looking for a reliable and experienced diagnostic laboratory chain in India. The company has a strong track record of success and is well-positioned for future growth. However, it is important to note that the healthcare sector is regulated, and LALPATHLAB could be affected by changes in government policy.

Some of the risks involved in investing in LALPATHLAB include:

  • The healthcare sector is regulated, and LALPATHLAB could be affected by changes in government policy.
  • The company’s services are subject to competition from other diagnostic laboratory chains, and LALPATHLAB needs to continue to invest in marketing and sales in order to maintain its market share.
  • The company’s services are subject to changes in technology, and LALPATHLAB needs to keep up with the latest technologies in order to continue to provide its services.

It is important to weigh these risks carefully before deciding whether or not to invest in LALPATHLAB.

Overall, LALPATHLAB is a well-managed and profitable company with a strong track record of success. However, investors should be aware of the risks involved in the healthcare sector before investing in the company.

Here are some additional details about Dr. Lal Path Labs Ltd.:

  • Products and services: A wide range of diagnostic tests, including blood tests, imaging tests, and molecular tests.
  • Headquarters: Delhi, India
  • Founded: 1983
  • Employees: 25,000+
  • Revenue: ₹25,000 crores (2021-22)
  • Market capitalization: ₹12,500 crores (2022-23)
          

Dr. Lal Path Labs Ltd. (LALPATHLAB) Chart

Technical Analysis of Dr. Lal Path Labs Ltd. (LALPATHLAB)

Moving Averages

PeriodSimpleExponential
MA 52,368.672,352.73
MA 102,303.952,320.64
MA 202,252.252,290.24
MA 302,257.272,280.66
MA 502,297.462,262.92
MA 1002,191.232,214.73
MA 2002,120.862,212.01

Moving Average Rating

Technical Indicators

NameValueNameValue
Aroon Up (14)92.86Aroon Down (14)0.00
MACD Level (12, 26)27.30MACD Signal (12, 26)6.73
Relative Strength Index (7)58.03Relative Strength Index (14)57.10
Stochastic %D (14 3 3)84.09Stochastic %K (14 3 3)79.90
Stochastic RSI Fast (3, 3, 14, 14)82.20Stochastic RSI Slow (3, 3, 14, 14)92.53
Bollinger Upper Band (20)2,402.51Bollinger Lower Band (20)2,101.99
Keltner Channels Upper Band (20)2,422.36Keltner Channels Lower Band (20)2,158.11
Donchian Channels Upper Band (20)2,442.20Donchian Channels Lower Band (20)2,157.25
Ichimoku Conversion Line (9, 26, 52, 26)2,311.35Ichimoku Base Line (9, 26, 52, 26)2,299.73
Ichimoku Leading Span A (9, 26, 52, 26)2,341.48Ichimoku Leading Span B (9, 26, 52, 26)2,207.53
Positive Directional Indicator (14)25.70Negative Directional Indicator (14)13.73
Volume Weighted Average Price2,353.87Volume Weighted Moving Average 202,301.28

Oscillator Rating

Oscillators

Awesome Oscillator99.13
Ultimate Oscillator (7,14,28)53.49
Money Flow (14)82.22
Chaikin Money Flow (20)0.04
Commodity Channel Index (20)106.71
Bull Bear Power107.82

High / Low

1 Month2,442.202,157.25
3 Month2,499.002,075.55
6 Month2,499.001,791.05
52 Week2,750.001,762.05
All Time4,245.50696.50

Volume

Volume177.9 T
Average 10 D331.9 T
Average 30 D188.6 T
Average 60 D227.1 T
Average 90 D253.1 T

Change/Volatility

Change-51.35 (-2.15%)
Change 1W3.80 (0.16%)
Change 1M163.70 (7.52%)
Volatility3.80
Volatility W3.57

Performance

Yesterday3.50
Weekly0.37
Monthly4.02
3 Month7.82
6 Month27.64
Yearly-1.90
5 Year151.89
All Time224.94

Misc.

Average Day Range (14)63.19
Average Directional Index (14)23.67
Average True Range (14)62.67
Williams Percent Range (14)-37.03
Rate Of Change (9)5.51
Hull Moving Average (9)2,416.83
Momentum (10)99.10
Parabolic SAR2,287.92

PIVOT POINTS of Dr. Lal Path Labs Ltd. (LALPATHLAB)

NameS3S2S1Pivot PointsR1R2R3
Classic1,788.532,016.632,096.272,244.732,324.372,472.832,700.93
Fibonacci2,016.632,103.772,157.602,244.732,331.872,385.702,472.83
Camarilla2,113.172,134.082,154.992,244.732,196.812,217.722,238.63
Woodie's1,839.252,002.182,067.352,230.272,295.452,458.372,523.55
DeMark's - - 2,056.452,224.832,284.55 - -

Financial Analysis of Dr. Lal Path Labs Ltd. (LALPATHLAB)

Income Statement

Basic EPS (FY)28.82
Basic EPS (TTM)31.78
EBITDA (Annual YoY Growth)-12.57
EBITDA (Quarterly QoQ Growth)26.47
EBITDA (Quarterly YoY Growth)24.43
EBITDA (TTM)5.2 B
EBITDA (TTM YoY Growth)5.99
EPS Diluted (Annual YoY Growth)-30.88
EPS Diluted (FY)28.74
EPS Diluted (MRQ)9.90
EPS Diluted (Quarterly QoQ Growth)45.22
EPS Diluted (Quarterly YoY Growth)42.30
EPS Diluted (TTM)31.67
EPS Diluted (TTM YoY Growth)-3.11
EPS Forecast (MRQ)10.95
Free Cash Flow (Annual YoY Growth)10.97
Free Cash Flow Margin (FY)21.55
Gross Profit (Annual YoY Growth)-9.47
Gross Profit (FY)7.3 B
Gross Profit (MRQ)2.1 B
Gross Profit (Quarterly QoQ Growth)14.72
Gross Profit (Quarterly YoY Growth)14.72
Gross Profit (TTM YoY Growth)5.11
Last Year Revenue (FY)20.2 B
Revenue (Annual YoY Growth)-3.38
Revenue per Employee (FY)5 M
Revenue (Quarterly QoQ Growth)10.18
Revenue (Quarterly YoY Growth)7.62
Revenue (TTM YoY Growth)3.61
Net Income (Annual YoY Growth)-30.74
Net Income (FY)2.4 B
Net Income (Quarterly QoQ Growth)45.68
Net Income (Quarterly YoY Growth)43.15
Net Income (TTM YoY Growth)-2.76
Total Revenue (FY)20.2 B

Valuation

Enterprise Value/EBITDA (TTM)38.46
Number of Employees4,048.00
Number of Shareholders186.4 T
Shares Float36.2 M
Price to Book (FY)11.64
Price to Earnings Ratio (TTM)73.86
Price to Revenue Ratio (TTM)9.49
Price to Sales (FY)9.64
Total Shares Outstanding82.8 M
Research & development Ratio (FY)0.18
Selling & Admin expenses Ratio (FY)18.18
Selling & Admin expenses Ratio (TTM)20.40

Balance Sheet

Total Assets (Annual YoY Growth)1.65
Total Debt (Annual YoY Growth)-21.23
Total Liabilities (FY)6.9 B
Cash & Equivalents (FY)2.6 B
Cash and short term investments (FY)8.2 B

Operating Metrics

Dividends

Dividend Yield Forward0.50
Dividends Paid (FY)-1,030,130,000.00
Dividends per Share (FY)12.00

Margins

Net Margin (FY)11.84
Net Margin (TTM)12.84
Gross Margin (FY)36.27
Gross Margin (TTM)38.36
Operating Margin (FY)17.27
Operating Margin (TTM)17.96
Pretax Margin (TTM)18.49

Dr. Lal Path Labs Ltd. (LALPATHLAB) FUTURES

ExpiryOpenHighLowCloseSettleContractsValueOIOI Change
28-Sep-232,410.002,410.002,313.752,344.852,344.851.6 T11.6 T778.8 T-126,000
26-Oct-232,400.952,404.802,327.802,352.802,352.806534.6 T195.6 T76.5 T
30-Nov-232,380.002,393.052,337.302,347.352,347.3512855.4 T0

Dr. Lal Path Labs Ltd. (LALPATHLAB) OPTIONS

Related Companies (Peers) to Dr. Lal Path Labs Ltd. (LALPATHLAB)

Price650.25 -2.35 (-0.36%)52 Week High699.70
ISININE08LI0102052 Week Low353.10
IndustryMedical/Nursing ServicesVolume53,955
SectorHealth ServicesP/E Ratio TTM33.30
Market Cap20.4 B1 Year Beta-0.62
Technical Rating of
Krsnaa Diagnostics Limited (KRSNAA) is a diagnostic imaging and pathology services provider based in India. It was founded in 2009 by Dr. Ashish Jain and is headquartered in Pune, Maharashtra. The company has a network of over 100 diagnostic centers across India. KRSNAA’s services include: Radiology: Krsnaa Diagnostics offers a range of radiology services, including more about Krsnaa Diagnostics Limited (KRSNAA)

Price83.95 -1.05 (-1.24%)52 Week High108.00
ISININE947I0101752 Week Low55.20
IndustryMedical/Nursing ServicesVolume3,374
SectorHealth ServicesP/E Ratio TTM42.72
Market Cap1.7 B1 Year Beta0.68
Technical Rating of
Lotus Eye Hospital and Institute Limited (LOTUSEYE) is an Indian eye care hospital chain headquartered in Chennai, Tamil Nadu. It was founded in 1986 by Dr. V. G. Raman. LOTUSEYE is one of the leading eye care hospital chains in India. LOTUSEYE offers a range of eye care services, including: Cataract surgery: LOTUSEYE offers cataract more about Lotus Eye Hospital and Institute Limited (LOTUSEYE)

Price137.10 -2.55 (-1.83%)52 Week High195.00
ISININE0CG60101652 Week Low76.00
IndustryMedical/Nursing ServicesVolume114,048
SectorHealth ServicesP/E Ratio TTM
Market Cap6 B1 Year Beta1.26
Technical Rating of
Max India Limited (MAXIND) is an Indian integrated healthcare company that was founded in 1981 and is headquartered in New Delhi, India. The company is one of the leading integrated healthcare companies in India. MAXIND has a strong focus on the Indian market. The company has a deep understanding of the Indian healthcare industry and more about Max India Limited (MAXIND)

Price1,417.75 -3.15 (-0.22%)52 Week High1,791.20
ISININE112L0102052 Week Low1,171.35
IndustryMedical/Nursing ServicesVolume168 T
SectorHealth ServicesP/E Ratio TTM52.67
Market Cap72.7 B1 Year Beta0.71
Technical Rating of
Metropolis Healthcare Limited (METROPOLIS) is an Indian diagnostic chain. The company was founded in 1998 and is headquartered in Mumbai, Maharashtra. Metropolis Healthcare Limited is one of the leading diagnostic chains in India. The company has a strong focus on the Indian market. The company has a deep understanding of the Indian diagnostic market and more about Metropolis Healthcare Limited (METROPOLIS)

Price562.45 -6.35 (-1.12%)52 Week High768.25
ISININE594H0101952 Week Low415.40
IndustryMedical/Nursing ServicesVolume42,818
SectorHealth ServicesP/E Ratio TTM53.85
Market Cap30.1 B1 Year Beta0.68
Technical Rating of
Thyrocare Technologies Limited (THYROCARE) is an Indian diagnostic laboratory chain headquartered in Mumbai, India. The company was founded in 1996 and is one of the leading diagnostic laboratory chains in India. THYROCARE offers a wide range of diagnostic tests, including: Blood tests: THYROCARE offers a range of blood tests, including complete blood count (CBC), liver more about Thyrocare Technologies Limited (THYROCARE)

Price455.60 -10.05 (-2.16%)52 Week High529.00
ISININE043W0102452 Week Low349.25
IndustryMedical/Nursing ServicesVolume101,003
SectorHealth ServicesP/E Ratio TTM49.96
Market Cap47.5 B1 Year Beta0.60
Technical Rating of
Vijaya Diagnostic Centre Limited (VIJAYA) is an Indian diagnostic laboratory chain headquartered in Hyderabad, Telangana, India. It was founded in 1981 by Dr. K. Vijayanand. VIJAYA is a leading diagnostic laboratory chain in India. It has a network of over 200 laboratories across India. The company offers a wide range of diagnostic tests, including: Blood more about Vijaya Diagnostic Centre Limited (VIJAYA)

Dr. Lal Path Labs Ltd. (LALPATHLAB) Related Indices

The Nifty 200 Index is designed to reflect the behaviour and performance of large and mid market capitalization companies . Nifty 200 includes all companies forming part of Nifty 100 and Nifty Full Midcap 100 index. The Nifty 200 Index represents about 86% of the free float market capitalization of the stocks listed on NSE as on March 31, 2016. The total traded value for the last six months ending March 2016, of all index constituents is approximately 77% of the traded value of all stocks on NSE. more about Nifty 200

The Nifty Total Market Index will track the performance of 750 stocks covering large, mid, small and microcap segments via a single index. All stocks that are part of Nifty 500 index and Nifty Microcap 250 index form part of the Nifty Total Market index. Stock’s weight is based on its free-float market capitalization. more about Nifty Total Market

The Nifty 500 represents the top 500 companies based on full market capitalisation and average daily turnover from the eligible universe. It represents about 94% of the free float market capitalization of the stocks listed on NSE as on March 31, 2016. The total traded value for the last six months ending March 2016, of all Index constituents is approximately 87% of the traded value of all stocks on NSE. more about Nifty 500

The Nifty500 Multicap 50:25:25 index aims to measure the performance of portfolio of large, mid and small market capitalisation companies with target weights assigned to each size segment. The Nifty500 Multicap 50:25:25 index includes all companies that are part of Nifty 500 index. While in Nifty 500 index, the total weight of each size segment (Large, Mid and Small cap) is based on the total free float market capitalisation of all stocks falling within that size segment, in Nifty500 Multicap 50:25:25 index, the total weight of each of these three segments (Large, Mid and Small cap) is fixed at 50%, 25% and 25% respectively at every quarterly rebalance date. The weight of 50%, 25% and 25% for the three segments are further divided amongst stocks within the respective segment based on underlying stock’s free float market capitalisation. Weight of each size segment may be different from its respective capped level between two rebalance dates due to price drift of underlying stocks. more about Nifty500 Multicap 50:25:25

Nifty Midcap 150 represents 150 companies (companies ranked 101-250) based on full market capitalisation from Nifty 500. The Nifty Midcap 150 Index represents about 11.4% of the free float market capitalization of the stocks listed on NSE as on March 31, 2016. The total traded value for the last six months ending March 2016, of all index constituents is approximately 19% of the traded value of all stocks on NSE. more about Nifty Midcap150

The Nifty Midcap 100 Index captures the movement of the midcap segment of the market. The Nifty Midcap 100 Index comprises 100 tradable stocks listed on the National Stock Exchange (NSE). The Nifty Midcap 100 Index represents about 11% of the free float market capitalization of the stocks listed on NSE as on March 31, 2018. The total traded value for the last six months ending March 2018, of all index constituents is approximately 20% of the traded value of all stocks on NSE. more about Nifty Midcap 100

The Nifty LargeMidcap 250 reflects the performance of a portfolio of 100 large cap and 150 mid cap companies listed on NSE, represented through the Nifty 100 and the Nifty Midcap 150 index respectively. The aggregate weight of large cap stocks and mid cap stocks is 50% each and are reset on a quarterly basis. The index has a base date of April 01, 2005 and a base value of 1000. The Index is reconstituted on a semi-annual basis along with Nifty 100 and Nifty Midcap 150 index. more about Nifty LargeMidcap 250

The Nifty MidSmallcap 400 Index is designed to reflect the behaviour and performance of the mid and small market capitalisation companies. The Nifty MidSmallcap 400 Index represents about 17% of the free float market capitalization of the stocks listed on NSE as on March 31, 2016. The total traded value for the last six months ending March 2016, of all index constituents is approximately 28% of the traded value of all stocks on NSE. more about Nifty MidSmallcap 400

The Nifty Healthcare Index is designed to reflect the behaviour and performance of the Healthcare companies. The Nifty Healthcare Index comprises of maximum of 20 stocks that are listed on the National Stock Exchange. more about Nifty Healthcare

The Nifty MidSmall Healthcare index tracks the performance of midcap and small cap stocks belonging to healthcare sector. Index includes upto 30 stocks. Stock weights are based on free-float market capitalization. more about Nifty MidSmall Healthcare

The Nifty MidSmall India Consumption index tracks the performance of the mid cap and small cap stocks representing domestic consumption theme. Companies with domestic operating revenues of more than 50% are considered eligible to be the part of the index. The index includes upto 30 stocks. The weight of each stock in the index is calculated based on its free-float market capitalization. more about Nifty MidSmall India Consumption

The Nifty Midcap150 Quality 50 Index includes top 50 companies from its parent Nifty Midcap 150 index, selected based on their ‘quality’ scores. The quality score for each company is determined based on return on equity, financial leverage (except for financial services companies) and earning per share (EPS) growth variability of each stock analysed during the previous 5 financial years. The weight of each stock in the index is based on a combination of stock’s quality score and its free float market capitalization. more about Nifty Midcap150 Quality 50

Nifty200 Quality 30 Index aims to cover companies which have durable business model resulting in sustained growth. This index consists of 30 companies selected from Nifty 200 index, based on Return on Equity, Debt equity ratio and Variability in EPS in the previous five years. The index series has a base date of April 01, 2005 and a base value of 1000. more about Nifty200 Quality 30

Leave a Reply

Your email address will not be published. Required fields are marked *

Stock Sectors
Stock Industries